AMETYST –  Observational Phase IV Study Following the Influence of Intramuscularly Administered Interferon Beta‑1a in Patients with Clinically Isolated Syndrome/ Clinically Definite Multiple Sclerosis


Authors: P. Štourač 1;  D. Horáková 2;  I. Mavrov 3;  P. Turčáni Za Tým Studie Ametyst 4
Authors‘ workplace: Neurologická klinika LF MU a FN Brno 1;  Neurologická klinika a Centrum klinických neurověd 1. LF UK a VFN v Praze 2;  Biogen Idec s. r. o., Praha 3;  I. neurologická klinika LF UK a UN Bratislava 4
Published in: Cesk Slov Neurol N 2014; 77/110(4): 465-472
Category: Original Paper

* za tým studie AMETYST

Sponzorem studie AMETYST je společnost Biogen Idec (Czech Republic) s.r.o., Na Pankráci 1683/127, 140 00 Praha 4.

Overview

Intramuscular interferon beta‑1a (IM IFNβ‑ 1a) exerts positive effect on a number of clinical parameters; it reduces number of relapses and slows down disability progression.

Aim:
The primary aim of the study is to evaluate quality of life and cognitive functions in patients treated with IM IFNβ‑ 1a using a visual analogue scale (VAS), Short Form Health Survey‑ 36 (SF‑ 36) and Paced Auditory Serial Addition Test (PASAT). As the secondary aim, the effects on relapse rate and disability progression (Expanded Disability Status Scale, EDSS) are also evaluated.

Patient sample and methods:
AMETYST is a prospective, observational, non‑interventional phase IV study in patients with Clinically Isolated Syndrome (CIS) or Clinically Definitive Multiple Sclerosis (CDMS) involving 14 Centres for the Treatment of Multiple Sclerosis (MS) in the Czech Republic and 10 Centres in the Slovak Republic. We present an interim analysis of 121 patients who completed 12 months of treatment with IM IFNβ‑ 1a.

Results:
Sociodemographic data were consistent with the general MS population. Within the last six months before treatment initiation, 65.3% patients experienced relapse, after six and 12 months of treatment, 9.2% and 14% of patients, respectively, had a relapse. EDSS, both SF‑ 36 domains and quality of life assessment by patients on VAS were stable throughout the treatment (p < 0.05). VAS evaluation by physicians and PASAT results were statistically significantly better following the treatment (30.0 vs 23.2; p < 0.001 for VAS and 82,7 vs 86,7; p < 0,05 for PASAT).

Conclusions:
The interim analysis confirmed significant effect of treatment with IM IFNβ – 1a on relapse rate reduction and stabilization of patients’ clinical status. Of the quality of life and cognition parameters, the treatment had a positive effect on physician‑ reported VAS and PASAT. Other evaluated parameters remained stable.

Key words:
multiple sclerosis – clinically isolated syndrome – quality of life – cognition – clinical course


Sources

1. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM, Murray TJ et al. Intramuscular interferon beta‑1a therapy initiated during a first demyelinating event in multiple sclerosis. N Eng J Med 2000; 343(13): 898– 904.

2. Kinkel RP, Kollman C, O’Connor P, Murray TJ, Simon JH, Arnold D et al. IM interferon beta‑1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology 2006; 66(5): 678– 684.

3. Miller DM, Kinkel RP. Health‑ related quality of life assessment in multiple sclerosis Rev Neurol Dis 2008; 5(2): 56– 64.

4. Ware JE jr, Kosinski M, Gandek B. How to score version 2 of the SF‑ 36 health survey: standards & acute forms. Lincoln RI: Quality Metric Incorporated: 2000.

5. Cutter GC, Beier ML, Rudick RA, Cookfair DL, Fischer JS, Petkau J et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain 1999; 122(5): 871– 882.

6. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM et al. Intramuscular interferon beta‑1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996; 39(3): 285– 294.

7. Rudick RA, Goodkin GE, Jacobs MD, Cookfair DL, Herndon RM, Richert JR et al. Impact of interferon beta‑1a on neurologic disability in relapsing multiple sclerosis.Neurology 1997; 49(2): 358– 363.

8. Vermersch P, de Seze J, Stojkovic T, Hautecoeur P.Interferon beta‑1a (Avonex) treatment in multiple sclerosis:similarity of effect on progression of dis­ability in patients with mild and moderate disability. J Neurol 2002; 249(2): 184– 187.

9. Simon JH, Jacobs LD, Campion M, Wende K, Simonian N, Cookfair DL et al. Magnetic resonance studies of intramuscular interferon beta‑1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research group. Ann Neurol 1998; 43(1): 79– 87.

10. Jongen PJ, Sindic C, Carton H, Zwanikken C, Lemmens W, Borm G et al. Improvement of health‑related quality of life in relapsing remitting multiple sclerosis patients after 2 years of treatment with intramuscular interferon beta‑1a. J Neurol 2010; 257(4): 584– 589. doi: 10.1007/ s00415‑ 009‑ 5378‑ x.

11. Lily O, McFadden E, Hensor E, Johnson M, Ford H.Disease‑ specific quality of life in multiple sclerosis: the effect of disease modifying treatment. Mult Scler 2006; 12(6): 808– 813.

12. Amato MP, Ponziani G, Rossi F, Liedl CL, Stefanile C,Rossi L. Quality of life in multiple sclerosis: the impact of depression, fatigue and disability. Mult Scler 2001; 7(5): 340– 344.

13. Zivadinov R, Zorzon M, Tommasi MA, Nasuelli D, Bernardi M, Monti‑Bragadin L et al. A longitudinal study of quality of life and side effects in patients with multiple sclerosis treated with interferon beta‑1a. J Neurol Sci 2003; 216(1): 113– 118.

14. Patti F, Capocardo M, Palermo F, Ciancio MR, Lopez R, Restivo D et al. Health‑related quality of life and depression in an Italian sample of multiple sclerosis patients. J Neurol Sci 2003; 211(1– 2): 55– 62.

15. Janssen ACJW, van Doorn PA, de Boer JB, Kalkers NF, van der Meché FG, Paschier J et al. Anxiety and depression influence the relation between disability status and quality of life in multiple sclerosis. Mult Scler 2003; 9(4): 397– 403.

16. Cohen JA, Cutter GR, Fischer JS, Goodman AD, Heidenreich FR, Kooijmans MF et al. Benefit of interferon beta‑1a on MSFC progression in secondary progressive MS. Neurology 2002; 59(5): 679– 687.

17. Arnoulds JH, Kilestein J, Pfennings L, Jelles B, Uitdehaag BM, Polman CH. Quality of life during the first 6 months of interferon‑beta treatment in patients with MS. Mult Scler 2000; 6(5): 338– 342.

18. Jongen PJ, Lehnick D, Sanders E, Seeldrayers P, Fredrikson S, Andersson M et al. Health‑related quality of life in relapsing‑ remitting multiple sclerosis patients during treatment with glatiramer acetate: a prospective, observational, international, multi‑center study. Health Qual Life Outcomes 2010; 8: 133. doi: 10.1186/ 1477‑ 7525‑ 8‑ 133.

Labels
Paediatric neurology Neurosurgery Neurology

Article was published in

Czech and Slovak Neurology and Neurosurgery

Issue 4

2014 Issue 4

Most read in this issue

This topic is also in:


Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account